Mirna Therapeutics, Inc. Appoints Clay B. Siegall, Ph.D., to its Board of Directors

Published: Jan 30, 2013

Mirna Therapeutics, a biotechnology company focused on the development and commercialization of microRNA (miRNA) therapeutics, today announced the appointment of Clay B. Siegall, Ph.D., co-founder, President, Chief Executive Officer and Chairman of Board of Directors of Seattle Genetics, as an outside director to its board of directors.

Back to news